Objective. Low bone mass, vertebral osteopenia and fractures have been described in patients with ankylosing spondylitis (AS), but the aetiology of this osteoporosis (OP) remains unknown. Insulin-like growth factor-I (IGF-I ), a bone-promoting peptide, may be considered as reflecting osteoblast function as well as its main binding protein, insulin-like growth factor binding protein-3 (IGFBP-3). Both were found to be decreased in post-menopausal women and male patients with idiopathic OP. In this study, we aimed to measure the circulating IGF-I and IGFBP-3 in AS patients.
A spondylitis (AS ) is an inflammatory
but is considered to exert endocrine actions. IGF-I is regulated by GH itself and also by its binding proteins rheumatic disease with a main involvement of the spine and sacroiliac joints. Sacroiliac joint pain and backache (IGFBPs) [6 ] . These proteins can modulate the bioavailability of IGF-I. There are currently six or are typical features of AS, and spine ankylosis is progressively induced by specific ossifications or synseven known circulating IGFBPs and they are all desmophytes. Osteoporosis (OP) is a complicating synthesized by osteoblasts. IGFBP-3 is the predominfeature of this condition [1] and there is some evidence ant protein that is linked to IGF-I. of a certain degree of osteopenia in AS: established It was recently reported that post-menopausal AS patients had a higher incidence of vertebral crush women [8] and male idiopathic osteoporotic patients fractures [2, 3] and a decreased bone mineral density [9] had decreased serum levels of IGF-I and IGFBP-3. (BMD) at the spine and the femoral neck [4] . This
It was thought that these lower IGF-I and IGFBP-3 lowered spine BMD was also observed in early AS levels reflected impaired osteoblastic function. Serum patients without syndesmophyte formation [5] . The markers of bone turnover have been assessed in AS in aetiology of this OP remains controversial; a reduced order to explain the OP of this condition. Serum range of spinal movement in ankylosing patients, the calcium, phosphorus and alkaline phosphatases were treatments given or the inflammatory cytokines could found to be normal, as well as osteocalcin (OC ) [10, contribute to this bone loss [1] . 11]. On the contrary, urinary excretion of markers of Insulin-like growth factor-I (IGF-I ), or somatomecollagen breakdown (i.e. pyridinium cross-links) [12, din C, is a bone-promoting peptide which mediates the 13] was found to be increased in some AS patients effect of growth hormone (GH ) at the tissue level, [14, 15] . including bone [6, 7] . It has primarily marked anabolic Since previous studies had suggested a possible actions on bone by increasing collagen gene expression pathological role for IGF-I and IGFBP-3 in the aetiand collagen synthesis, and inducing preosteoblast ology of common OP, and these factors could reflect differentiation and proliferation. Thus, IGF-I proosteoblast function, we aimed to measure the circulatmotes bone formation. It is produced by various tissues ing IGF-I and IGFBP-3 in AS patients. and has autocrine and paracrine actions. The circulating IGF-I is presumed to be mainly derived from liver, PATIENTS AND METHODS
Patients
Thirty-three patients satisfying the modified New York criteria for AS [16 ] were studied. This group © 1998 British Society for Rheumatology included 23 males and 10 females. The mean age was femoral neck by dual X-ray absorptiometer (SOPHOS XRA, Sopha Medical, Buc, France). Results were 38.5 yr (± 14.8) and the mean disease duration was 6.2 yr (± 5). Twenty-five patients had the HLA B27
given as bone mineral density and T score, which correspond to the number of standard deviations of antigen. There were no post-menopausal women. No patient had psoriasis or inflammatory bowel disease.
any result from the peak bone mass-related population mean (the normal ranges were provided by the manuAll the patients took non-steroidal anti-inflammatory drugs and 14 had received corticosteroids (administrafacturers of the bone densitometer). The BMI was determined for patients and controls. tion of steroids was intermittent with a daily dose of <15 mg prednisolone and during a maximal period of 3 months). No steroids were given 3 months prior to Statistical analysis Results are given as the mean ± .. Statistical siginclusion in this study. Twenty-two patients had exclusive axial disease and 11 peripheral disease with evinificance was estimated by Student's t-test. The correlation between variables was analysed by Spearman's dence of arthritis (swollen joint or joint effusion). The radiological sacroiliac joint changes (sacroiliitis) and test. The level of significance was <0.05. the dorsolumbar X-ray features (for the presence of RESULTS syndesmophytes) were analysed for the study group. The patients were assessed by two physicians ( ET, Details on the clinical and radiological features of the AS group are summarized in Table I . The levels of DW ) for Schober's test. A clinical index of disease activity (Bath Ankylosing Spondylitis Disease Activity the different serum bone markers (calcaemia, PTH, 25OHD 3 , tAP and OC ) were in the normal range Index; BASDAI ) [17] was also evaluated. Laboratory activity was assessed by the Westergren erythrocyte without difference between AS and controls ( Table II ) . As expected, the lumbar spine BMD was significantly sedimentation rate ( ESR) and the C-reactive protein (CRP). lowered in AS patients as compared to controls (P = 0.05) and the corresponding T score was also Patients excluded from this study corresponded to post-menopausal women, patients with a condition or decreased in this group (P = 0.04). The femoral neck BMD and T score were also found to be decreased in a treatment which might alter the bone mineral metabolism (Paget's disease, hyperthyroidism, hyperparathythe patient group, but results did not reach the significant level (BMD, P = 0.19; T score, P = 0.17) roidism, ongoing corticosteroid therapy, thyroxine and anticonvulsants). Patients with diabetes mellitus, obes- ( Table II ) . Lumbar spine and femoral neck BMD did not differ between patients who had had corticosteroids ity, underweight or liver disease were also excluded. Obesity was defined by a body mass index (BMI ) and patients who had not lumbar spine BMD: AS with previous steroid administration = 0.96 g/cm2 between 30 and 40 kg/m2 (subjects with a BMI of >40 kg/m2 were also considered obese) [18] and sub-(T score = − 1.32) and AS without steroids = 0.94 g/cm2 (T score = − 1.44) (P = 0.65); femoral jects with a BMI of <18 kg/m2 were defined as underweight.
neck BDM: AS with previous steroid administration = 0.74 g/cm2 (T score = − 1.63) and AS without steroids = 0.80 g/cm2 (T score = − 1.11) (P = 0.22).
Controls
The control group included 23 healthy volunteers
The mean values of the BMI were similar in AS and controls. (mean age 35.8 ± 9.5 yr; 13 males and 10 females; no post-menopausal women) without a history of There were no significant differences in the mean values for the serum parameters including insulin, GH inflammatory rheumatic disease or condition responsible for bone loss. The exclusion criteria were the and IGF-I. Although no subjects had diabetes mellitus, AS patients were found to have higher glycaemia than same as for the AS group. BMD was measured at the lumbar spine and the [19] . A parallel decline in serum and skeletal IGF-I in aging human was reported [19] . It has been demon- density in post-menopausal women [7] , that IGF-I serum levels were decreased in post-menopausal OP is synthesized by the osteoblast cell lineage [6, 19] .
The role of this protein, as well as the others, is still not well understood, but it is thought that it modulates IGF-I, insulin-like growth factor I; IGFBP-3, insulin-like growth factor binding protein-3; 25 OHD 3 , 25 hydroxyvitamin D.
growth factor availability and activity. Serum levels of IGFBP-3 are dependent on GH and thus reflect GH secretion. GH stimulates accumulation of IGFBP-3 by controls (P = 0.02). However, all the glycaemia values were in the normal range (3.83-6 .05 mmol/l ). Levels osteoblasts and IGFBP-3 may increase the biological action of IGF-I in bone [6 ] . There were some implicaof IGFBP-3 were significantly reduced in AS patients (AS: 3.29 mg/ml, controls: 3.63 mg/ml; P = 0.05).
tions of this IGFBP in OP since serum IGFBP-3 was found to be decreased in post-menopausal OP [8] . All In the patient group, no correlation was observed between the IGF-I or IGFBP-3 serum concentrations these recent data suggested that alteration in the synthesis of IGF-I, its receptor binding or IGFBP could and the lumbar spine and femoral neck BMD. Furthermore, there were no relationships between the play a role in the pathogenesis of OP [19] . In AS, bone loss leading to generalized OP is a IGF-I serum values and the different indices of bone turnover (i.e. PTH, calcaemia, 25OHD 3 and tAP) complicating feature of the disease [1] . We have measured BMD in AS patients and found a significantly excluding OC. Indeed, there was a positive correlation between serum levels of IGF-I and OC (r = 0.39; P = lowered BMD and T score at the lumbar spine. These data are consistent with previous studies of BMD 0.02). No similar result was observed for IGFBP-3 and OC (r = −0.02; P = 0.9) nor were there any assessment in AS [4] . In this series of patients with lowered spine BMD, and on the contrary in postrelationships between the serum IGFBP-3 levels and other markers of bone turnover (calcaemia, PTH, tAP menopausal OP, we found no decreased concentrations of IGF-I. However, serum levels of IGFBP-3 were and 25OHD
3 ). Finally, IGFBP-3 correlated negatively with ESR significantly lower amongst patients than controls. It has been demonstrated that IGFBP-3 plays an import-(r = −0.39; P = 0.025), but there was no relationship between IGF-I and this parameter of inflammation.
ant role in the IGF-I activity in osteoblastic cells. Therefore, it may be hypothesized that the decreased Furthermore, no correlation of IGF-I and IGFBP-3 with CRP and the BASDAI could be shown.
concentrations of IGFBP-3 could impair the activity of this growth factor in our patients.
DISCUSSION
Another implication of these data is the regulation of IGF-I and IGFBP-3 by GH. Both are dependent Our study was undertaken to determine the serum levels of IGF-I and IGFBP-3 as markers of bone on GH itself and reflect endogenous GH secretion. In our study, no differences in the basal serum values of formation in AS. There is growing evidence that this bone growth factor and its main binding protein are GH were observed between patients and controls.
Since the determination of IGF-I levels was normal in clearly important factors in bone physiology and pathology [6, 7, 19] . Indeed, IGF-I has a marked AS, it is difficult to speculate diminished GH secretion. However, no stimulating tests for GH secretion were anabolic effect on bone by different mechanisms and is implicated in OP at different levels [6 ] . A negative performed.
IGF-I and its IGFBPs have not been previously A evaluated in adult patients with chronic inflammatory This work was supported by a grant from La diseases. They were studied in juvenile chronic arthritis Société Française de Rhumatologie. (JCA) because these conditions are frequently complicated by growth delay [22] . Several studies had there-R fore focused on the determination of IGF-I levels in
